Search Results

MC# 16-14
A Phase I/Ib, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

MC# 19-11
A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria

MC# 19-16
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients with Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment

MC# 19-22
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma

MC# 19-30
Phase Ib/II Open-Label Study Evaluating Tazemetostat in Combination with Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects with Metastatic Castration Resistant Prostate Cancer

MC# 19-32
A Phase I Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy

MC# 19-34
A Phase II Trial: Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Adolescent and Young Adult (AYA) Subjects with Advanced Malignancies Involving the Central Nervous System (CNS)

MC# 19-40
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)

MC# 20-03
A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung

MC# 18-26
A Phase I/II Study of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

MC# 19-09
A Phase I, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 in Patients with Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies

MC# 19-10
A Phase Ib Study of ARQ 751 as a Single Agent or in Combination with Other Anti-cancer Agents in Adult Subjects with Advanced Solid Tumors with PIK3CA/AKT/PTEN Mutations

MC# 19-17
A Phase I, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of PSB205 in Patients with Relapsed/Refractory Solid Tumors

MC# 19-19
A Phase I, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-200 via Intravenous Infusion in Patients with Advanced Solid Tumors

MC# 19-27
A Phase I Study of AGEN2373, an Anti-CD137 Monoclonal Antibody in Subjects with Advanced Cancer

MC# 19-37
A Phase Ib, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

MC# 20-02
An Open-Label Study of the Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients with Solid Tumors

MC# 19-31
A Phase I, Open-label, Multicenter Study of SYNB1891 Administered by Intratumoral Injection to Patients with Advanced/Metastatic Solid Tumors and Lymphoma Alone and in Combination with Atezolizumab

MC# 17-36
First-in-Human, Open-Label, Dose-Escalation Trial with Expansion Cohorts to Evaluate Safety of Axl-Specific Antibody-Drug Conjugate (enapotamab vedotin,HuMax®-AXL-ADC) in Patients with Solid Tumors

MC# 19-21
A Phase I/IIa Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin Expression Who Have Failed Standard Available Therapy

MC# 19-26
A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination with Rucaparib in Patients with Advanced Breast, Ovarian, or Prostate Cancer

MC# 19-04
Phase I Study of KN026 in HER2 Expressing Breast Cancer, Gastric/Gastroesophageal Junction Cancer and other Locally Advanced/Metastatic Solid Tumors

MC# 19-25
A Phase I open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors

MC# 19-35
A Phase I/II Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

MC# 18-17
A Phase I Study of RGX-202, a Small Molecule Inhibitor of the Creatine Transporter, SLC6a8, with or without FOLFIRI in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts